Does the media refer more to SDGR or MANE?

In the previous week, Veradermics had 2 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Veradermics and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat Veradermics' score of 0.39 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VKTX or SDGR?

In the previous week, Viking Therapeutics had 14 more articles in the media than Schrodinger. MarketBeat recorded 17 mentions for Viking Therapeutics and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat Viking Therapeutics' score of 0.39 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SDGR or TNGX?

In the previous week, Schrodinger and Schrodinger both had 3 articles in the media. Schrodinger's average media sentiment score of 1.26 beat Tango Therapeutics' score of 1.24 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACAD or SDGR?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Schrodinger. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat ACADIA Pharmaceuticals' score of 1.02 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SDGR or NAMS?

In the previous week, NewAmsterdam Pharma had 7 more articles in the media than Schrodinger. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat NewAmsterdam Pharma's score of 1.10 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Schrodinger (SDGR) Competitors

$14.97 -0.16 (-1.06%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$14.90 -0.07 (-0.45%)

As of 07/24/2026 07:34 PM Eastern

Compare

SDGR vs. MANE, VKTX, TNGX, ACAD, and NAMS

Should you buy Schrodinger stock or one of its competitors? MarketBeat compares Schrodinger with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Schrodinger include Veradermics (MANE), Viking Therapeutics (VKTX), Tango Therapeutics (TNGX), ACADIA Pharmaceuticals (ACAD), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does Schrodinger compare to Veradermics?

Schrodinger (NASDAQ:SDGR) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 35.27%. Veradermics has a consensus target price of $153.00, suggesting a potential upside of 39.32%. Given Veradermics' stronger consensus rating and higher probable upside, analysts plainly believe Veradermics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Veradermics had 2 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Veradermics and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat Veradermics' score of 0.39 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.1% of Schrodinger shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Veradermics' return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Veradermics	N/A	N/A	N/A

Veradermics has lower revenue, but higher earnings than Schrodinger. Veradermics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Summary

Veradermics beats Schrodinger on 8 of the 13 factors compared between the two stocks.

How does Schrodinger compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Viking Therapeutics presently has a consensus target price of $97.00, indicating a potential upside of 178.82%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 35.27%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Viking Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Viking Therapeutics had 14 more articles in the media than Schrodinger. MarketBeat recorded 17 mentions for Viking Therapeutics and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat Viking Therapeutics' score of 0.39 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Schrodinger	-40.61%	-30.85%	-15.32%

Schrodinger has higher revenue and earnings than Viking Therapeutics. Schrodinger is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A

Summary

Schrodinger beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Schrodinger compare to Tango Therapeutics?

Schrodinger (NASDAQ:SDGR) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Schrodinger and Schrodinger both had 3 articles in the media. Schrodinger's average media sentiment score of 1.26 beat Tango Therapeutics' score of 1.24 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Schrodinger has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Tango Therapeutics	N/A	-41.54%	-33.44%

Schrodinger presently has a consensus price target of $20.25, indicating a potential upside of 35.27%. Tango Therapeutics has a consensus price target of $42.15, indicating a potential upside of 58.29%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics has lower revenue, but higher earnings than Schrodinger. Tango Therapeutics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A
Tango Therapeutics	$62.38M	61.75	-$101.59M	-$0.83	N/A

Summary

Schrodinger beats Tango Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Schrodinger compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

ACADIA Pharmaceuticals currently has a consensus price target of $33.17, suggesting a potential upside of 33.52%. Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 35.27%. Given Schrodinger's higher possible upside, analysts plainly believe Schrodinger is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.67
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Schrodinger's net margin of -40.61%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Schrodinger	-40.61%	-30.85%	-15.32%

ACADIA Pharmaceuticals has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.97	$391M	$2.20	11.29
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A

ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Schrodinger. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat ACADIA Pharmaceuticals' score of 1.02 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Schrodinger on 12 of the 16 factors compared between the two stocks.

How does Schrodinger compare to NewAmsterdam Pharma?

Schrodinger (NASDAQ:SDGR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, NewAmsterdam Pharma had 7 more articles in the media than Schrodinger. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.26 beat NewAmsterdam Pharma's score of 1.10 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 35.27%. NewAmsterdam Pharma has a consensus target price of $49.42, suggesting a potential upside of 66.72%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Schrodinger has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Schrodinger has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$254.91M	4.34	-$103.26M	-$1.41	N/A
NewAmsterdam Pharma	$22.50M	154.00	-$203.82M	-$1.79	N/A

Schrodinger has a net margin of -40.61% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

NewAmsterdam Pharma beats Schrodinger on 9 of the 17 factors compared between the two stocks.

Get Schrodinger News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SDGR vs. The Competition

Export

Metric	Schrodinger	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.12B	$1.70B	$6.88B	$12.25B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	-10.62	74.42	27.00	23.71
Price / Sales	4.34	23.69	492.66	73.79
Price / Cash	N/A	26.11	50.54	59.64
Price / Book	3.03	4.98	10.28	6.07
Net Income	-$103.26M	-$54.76M	$3.60B	$331.84M
7 Day Performance	-2.28%	-6.77%	-1.25%	-1.53%
1 Month Performance	-7.25%	-2.41%	-0.35%	-2.46%
1 Year Performance	-32.66%	-11.02%	18.41%	13.66%

Schrodinger Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SDGR Schrodinger	2.3341 of 5 stars	$14.97 -1.1%	$20.25 +35.3%	-33.4%	$1.12B	$254.91M	N/A	790	Positive News
MANE Veradermics	2.7267 of 5 stars	$110.40 -7.7%	$135.60 +22.8%	N/A	$4.61B	N/A	N/A	19
VKTX Viking Therapeutics	3.3662 of 5 stars	$38.12 -1.9%	$93.60 +145.5%	+3.9%	$4.51B	N/A	N/A	20	Upcoming Earnings
TNGX Tango Therapeutics	2.3693 of 5 stars	$28.36 -8.7%	$41.50 +46.3%	+294.5%	$4.49B	$62.38M	N/A	90	Positive News
ACAD ACADIA Pharmaceuticals	4.693 of 5 stars	$25.50 -2.7%	$32.94 +29.2%	+7.8%	$4.49B	$1.07B	11.59	510	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SDGR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Schrodinger (SDGR) Competitors

SDGR vs. MANE, VKTX, TNGX, ACAD, and NAMS

How does Schrodinger compare to Veradermics?

Summary

How does Schrodinger compare to Viking Therapeutics?

Summary

How does Schrodinger compare to Tango Therapeutics?

Summary

How does Schrodinger compare to ACADIA Pharmaceuticals?

Summary

How does Schrodinger compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR vs. The Competition

Schrodinger Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Schrodinger (SDGR) Competitors

SDGR vs. MANE, VKTX, TNGX, ACAD, and NAMS

How does Schrodinger compare to Veradermics?

Do analysts rate SDGR or MANE?

Does the media refer more to SDGR or MANE?

Do insiders and institutionals hold more shares of SDGR or MANE?

Is SDGR or MANE more profitable?

Which has stronger earnings and valuation, SDGR or MANE?

Summary

How does Schrodinger compare to Viking Therapeutics?

Do analysts rate VKTX or SDGR?

Which has more volatility & risk, VKTX or SDGR?

Do insiders & institutionals have more ownership in VKTX or SDGR?

Does the media favor VKTX or SDGR?

Is VKTX or SDGR more profitable?

Which has higher earnings and valuation, VKTX or SDGR?

Summary

How does Schrodinger compare to Tango Therapeutics?

Does the media prefer SDGR or TNGX?

Which has more risk and volatility, SDGR or TNGX?

Is SDGR or TNGX more profitable?

Do analysts rate SDGR or TNGX?

Do insiders and institutionals believe in SDGR or TNGX?

Which has better earnings and valuation, SDGR or TNGX?

Summary

How does Schrodinger compare to ACADIA Pharmaceuticals?

Do analysts prefer ACAD or SDGR?

Is ACAD or SDGR more profitable?

Which has stronger earnings & valuation, ACAD or SDGR?

Which has more risk and volatility, ACAD or SDGR?

Does the media favor ACAD or SDGR?

Do insiders & institutionals hold more shares of ACAD or SDGR?

Summary

How does Schrodinger compare to NewAmsterdam Pharma?

Do insiders and institutionals have more ownership in SDGR or NAMS?

Does the media prefer SDGR or NAMS?

Do analysts prefer SDGR or NAMS?

Which has more risk & volatility, SDGR or NAMS?

Which has preferable valuation & earnings, SDGR or NAMS?

Is SDGR or NAMS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR vs. The Competition

Schrodinger Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools